A new metabolic mechanism describes how tumors disable “gatekeeper” cells to prevent immune response to cancer.

St. Jude Children's Research Hospital scientists have discovered how tumors disable immune "gatekeeper" cells that alert the rest of the immune system to the presence of cancer - and how restoring ...

Treating the brain cancer glioblastoma (GBM) demands more than conventional strategies due to a mix of factors including the cancer’s genetic complexity, invasive growth, and immune resistance. A new ...

St. Jude Children's Research Hospital scientists have discovered how tumors disable immune "gatekeeper" cells that alert the ...

The field of cancer immunology has seen significant advancements in recent years, particularly with the emergence of immunotherapy as a key pillar in the ...

Phase 2 study of programmed death-1 antibody (anti-PD-1, MK-3475) in patients with microsatellite unstable (MSI) tumors. Safety and immunologic efficacy of personalized multiple HLA class I-restricted ...

Booking Health, a global medical travel provider, announced today the release of its 2026 report on advanced head and neck cancer treatment for international patients, outlining key developments in ...

Favorable safety profile and encouraging early efficacy signals support advancement to Phase II trial of dendritic cell vaccine for the treatment of glioblastoma. HOUSTON, June 2, 2025 /PRNewswire/ -- ...

The Pan Am Cancer Treatment Centers was started in 2009 to provide patients cutting edge personalized immunotherapies including dendritic cells, allogeneic NK cells, and neoantigen peptide vaccination ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

To date, human anti-tumor vaccination has not delivered on its promises. Reasons for failure include tumor immune escape mechanisms, limited availability of tumor specific antigens, as well as failure ...

Some studies have suggested that morning is the optimal time for immunotherapy, but a new analysis of patients with lung ...